Resources

Why and when to use this therapy to treat patients who have type 2 diabetes.

Method to identify prediabetes found to impact risk of heart disease or death.

New research shows how estrogen treatment helps to control blood sugar levels after menopause.

Risk for stroke significantly increased, but exceeded by heart failure

Subanalysis of CANVAS program shows slower progression of kidney disease, reduction in weight, reduction in A1c and even drop in blood pressure.

Mr. Hernandez' lab results are A1C 7.5%, FPG 137 mg/dL, LDL 190 mg/dL, HDL 38 mg/DL and triglycerides 232 mg/dL. He is started on metformin, lifestyle modifications, an ACE inhibitor, and a statin. He was asked to return in 3 months' time to evaluate how everything is going. However, he fails to keep his appointment. He returns 1 year after his initial diagnosis for a recurrent yeast infection. His A1C is currently 7.7%. Upon questioning, he admits that while he has been good about taking his “heart meds,” he has not taken the “sugar pill” because he didn’t like it. What side effect did the patient most likely find intolerable? A. Diarrhea and abdominal cramping B. Paresthesias C. Increased appetite D. Insomnia Follow the link for the answer.

The American College of Physicians (ACP) has issued a new recommendation that type 2 patients should not have a target A1C level below 8 percent for any patient population and should not have any A1C targets for older adults (e.g., age 80 and older) or younger individuals with limited life expectancy because of other serious diseases and illnesses. Do you agree with the American College of Physicians' new A1C target recommendations? Follow the link to share your opinion.

You may wonder which CGM monitor is best for your patients. I know I do. Learn from Dr. Stephen W. Ponder, MD, FAAP, CDE-AADE Educator of the Year, Board Certified Pediatric Endocrinologist, Pediatric Residency Program Director at Baylor Scott & White McLane Children's Hospital and 50 year Joslin Medalist. He also helps people with diabetes through the "sugar surfing" method to empower individuals who have diabetes to live fuller and more satisfying lives.

In part 5, the conclusion of this Exclusive Interview, Dr. Swapnil N. Rajpathak talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about upcoming research studies on patient adherence.

In this week's Homerun Slides, defining albuminuria, a marker for kidney dysfunction.